No Data
The Market Doesn't Like What It Sees From Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues Yet As Shares Tumble 30%
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. : The Sangamo Therapeutics (SGMO.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $5.00.
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target